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Abstract:
Depression is a significant health issue with treatment resistance reported in about one third of
patients. Treatment resistance results in significant disability, impaired quality of life, and
increased healthcare costs. Repetitive transcranial magnetic stimulation (rTMS) is a treatment
option for treatment resistant depression (TRD) with an average response rate of around 30%.
Theta-burst is a novel rTMS paradigm that has shown promise as a treatment for TRD in some
preliminary studies. In a naturalistic design, we evaluated the efficacy and tolerability of bilateral
sequential (right then left) prefrontal theta-burst rTMS (bsTBS) in 50 patients with TRD (600
pulses/session, 20 sessions, 100% of resting motor threshold (two patients treated at 80% due to
intolerance of 100%), F4/F3 of 10-20-20 EEG localization). Data was collected over 36 months
from a specialized academic TMS clinic. Patients had multiple-treatment resistance with at least
two failed trials of different antidepressants with 20% also having failed electroconvulsive
therapy and 66% having received professional therapy. We found a 28% remission rate (HAMD17 score of ≤ 7) and a 52% response rate (≥ 50% reduction in HAMD-17) with a 42% reduction
in average HAMD-17 score. The treatment was well tolerated, with muscle contractions, mild
pain or discomfort, headache, scalp irritation, and changes to vitals being captured as occasional
adverse events with two instances of syncope (0.22% of treatments). This naturalistic study
shows that bsTBS is a promising paradigm for a multiple-TRD patient population with
approximately one-third of treatments achieving remission and over half achieving significant
response.
Keywords (6 max): Treatment Resistant Depression, Bilateral Theta Burst, Transcranial
Magnetic Stimulation, Remission, Antidepressant effect
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Neurostimulation is an increasingly common means of treating depression and is
endorsed by the CANMAT guidelines for the treatment of depression (Milev et al., 2016). As
depression is associated with asymmetric functional changes (PET and EEG) with hyperactive
right and hypoactive left DLPFC activity (Kennedy et al., 1997), rTMS trials often aim to induce
either inhibitory plasticity using low frequency pulses to the right or excitatory plasticity using
high frequency stimulation to the left DLPFC. Both can also be combined in a bilateral
stimulation protocol. Most studies have failed to find evidence of superiority for bilateral vs.
unilateral stimulation using standard rTMS (Blumberger et al., 2012; Fitzgerald et al., 2013,
2012; Loo et al., 2003; Pallanti et al., 2010) although bilateral treatment is well tolerated (Berlim
et al., 2013; Blumberger et al., 2016). The most widely used, rTMS paradigm for treating
depression involves applying 3000 pulses of 10 Hz over 37.5 minutes to the left dorsolateral
prefrontal cortex (dlPFC) (George, 2010). These commonly used rTMS paradigms result in
remission in 37.1% of patients with treatment resistant depression (TRD; 2.5 ± 2.4 adequate
antidepressant trials on average) based on Clinical Global Impression (CGI) scores (Carpenter et
al., 2012). While this response rate is encouraging, it is widely recognised that the potential
clinical benefits of brain stimulation can be much higher, if the stimulus delivery protocols can
be optimised.
Theta burst stimulation (TBS) is a promising patterned form of rTMS, that delivers triplet
bursts of energy (50 Hz), at a rate of 5 Hz (Huang et al., 2005). This form of stimulation shares
similarities to endogenous neural signaling and can influence neuroplasticity based on how it is
administered. When applied continuously (cTBS) it induces long-term depression (LTD) of the
target area, inhibiting plasticity; when administered intermittently (iTBS), it induces long-term
potentiation (LTP) of the target area, enhancing plasticity (Di Lazzaro et al., 2011; Huang et al.,
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2005; Suppa et al., 2016). It also has the advantage of reducing administration duration (Chung
et al., 2015) from 20-45 minutes to 1-3 minutes. There is preliminary evidence of safety,
efficacy, and tolerability of prefrontal theta-burst stimulation in treating depression (Berlim et
al., 2017; Cao et al., 2018; Chistyakov et al., 2010; Holzer and Padberg, 2010; Li et al., 2014).
Some studies investigated sequential bilateral theta-burst rTMS (bsTBS) in TRD with cTBS to
the right dlPFC and then iTBS to the left dlPFC. Some studies were positive (Li et al., 2014;
Plewnia et al., 2014) but others were negative (Prasser et al., 2015). The lower number of
sessions (15) and low energy level (80% RMT) used might have contributed to these negative
results.
Our clinic receives referrals for those with a high level of TRD. Typically, patients have
failed several trials of medications and combination therapy. However, the optimal paradigm for
these treatments remains a work in progress. In order to optimize the treatment outcome, we
chose to target prefrontal areas bilaterally starting with right side cTBS to induce inhibition and
pre-condition the left side, followed with left prefrontal area stimulation using iTBS, which is
thought to be excitatory. The objective of this study was to assess the response and remission
rates of bsTBS in a treatment resistant group of unipolar depressed subjects with ongoing
medication and psychotherapy in a naturalistic, retrospective study setting.
Methods
Sample and Outcome Measures
This is a retrospective study and was conducted in accordance with the Declaration of
Helsinki and was approved by the Western University office of Human Research Ethics Board
(WREM) at St. Joseph’s Health Care London. Anonymized data was collected retrospectively,
and so informed consent was not required for data acquisition, though all patients consented for
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the treatment at the outset. Routinely collected measurements of depression and anxiety at
baseline and after treatment were used from the on-site hospital-based therapeutic brain
stimulation clinic at Parkwood Institute Mental Health Care Building. The assessments used
include the 17-item Hamilton Depression Rating Scale (HAMD-17) (Hamilton, 1960), selfreport 9-item Patient Health Questionnaire (PHQ-9) (Spitzer et al., 1999), and 7-item
Generalized Anxiety Disorder scale (GAD-7) (Spitzer et al., 2006). Data was collected on all
adults treated with bsTBS between July 2015 and January 2018. Participants were included if
they were between 19 and 80 years old and suffered from treatment resistant unipolar depression
as defined by inadequate response (minimal or no improvement) to 2 or more adequate trials of
antidepressants from two different drug classes and HAMD-17 ≥ 10.
The primary efficacy measure was defined as a change in HAMD-17 score from baseline
to end of treatment. Secondary outcomes included change in PHQ-9 and GAD. A clinical
response was defined as ≥ 50% reduction of baseline scores on the HAMD-17 scale and
remission was defined by HAMD-17 scores ≤ 7 (Leucht et al., 2013).
Data analysis
The Statistical Package for the Social Sciences (SPSS 17.0; SPSS, Inc., Chicago IL.,
USA) was used to run paired t-tests. Scores at baseline for the HAMD-17 (primary outcome),
PHQ-9, and GAD were compared to their respective scores at the end of 20 treatment sessions
over four weeks. All differences, statistically significant to the p < .05 threshold, were reported.
The percentage of the participants that responded (≥ 50% reduction in baseline HAM-D17 score)
and remitted (HAMD-17 scores ≤ 7) following treatment were also calculated along with the
average percent decrease from baseline to end of treatment for each measure.
Treatment
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In our academic specialized brain stimulation clinic, a TMS Magstim Super Rapid 2
machine (The Magstim Company Ltd™., UK) was used to sequentially apply cTBS at the F4
location of the international 10-20-20 EEG localization system (right dlPFC) followed by iTBS
at the F3 location (left dlPFC). Each location received 600 pulses in bursts of 40-50Hz at a rate
of 5Hz (theta range) and at 100% of the resting motor threshold (RMT) as established by
induction of a visible motor response in the hypothenar hand muscle in 3/5 trials. We allowed the
burst frequency to vary between 40-50 Hz to allow treatment at 100% RMT. Tolerability was
assessed by any adverse effects during and after each treatment. Twenty sessions were delivered
4-5 days per week. In two cases (4%) the patient could not tolerate the local sensation at 100%
energy of the RMT and it was reduced to 80% of RMT.
Results
Of the subjects included in this naturalistic observational study (n = 50; 47 ± 13.3 years
old; 54% female), 10 (20%) had received electroconvulsive therapy and 34 (66%) had received
either cognitive behavioural therapy or interpersonal psychotherapy in their lifetime. This was in
addition to failing at least two adequate trials of antidepressant medications from different
classes in an attempt to treat the current episode, meeting criteria for multiple-TRD (McAllisterWilliams et al., 2018).
Within 20 treatment sessions of bsTBS, 14 participants (28%) achieved remission
(HAMD-17 scores ≤ 7) and an additional 12 participants responded to treatment (≥ 50%
reduction in baseline HAM-D17 score) for a total response rate of 52%. Changes in the average
score for each measure from pre- to post-treatment are reported in Figure 1. On average, the
HAMD-17 score improved significantly (t(50) = 7.15, p < 0.001) by 43.12% from baseline (M =
22.08, SD = 5.97) to after 20 treatment sessions (M = 12.56, SD = 7.28). The mean PHQ-9 score
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also improved significantly (t(50) = 6.02, p < 0.001) by 37.05% from 19 ± 4.53 at baseline (M =
19.00, SD = 4.53) to after 20 treatment sessions (M = 11.96, SD = 6.92). Finally, the mean GAD
score also improved significantly (t(50) = 7.41, p < 0.001) by 36.71% from baseline (M = 13.62,
SD = 4.72) to after 20 treatment sessions (M = 8.62, SD = 6.21). Of the 10 patients who had
previously had ECT treatment, seven achieved remission following 20 sessions of treatment.
Adverse events were captured for 92% of the sample and are reported in Table 1.
Discussion
In this paper we describe the results of a retrospective chart review study completed at an
academic therapeutic brain stimulation clinic. All patients included were unipolar major
depressive disorder patients with multiple-treatment resistance (at least 2 or more adequate
antidepressant trials). Most had failed formal psychotherapy, and some had failed trials of ECT.
The paradigm we used in our clinic is novel and involves sequential right then left prefrontal
rTMS using continuous then intermittent theta burst stimulation respectively, each 600 pulses.
This paradigm was delivered in 10 minutes on average using a Magstim Superrapid 2 machine.
The results indicate significant improvement of depressive symptoms on a standardized clinical
depression rating scale (HAMD-17) as well as patient rating (PHQ-9) and a standardized
assessment of anxiety (GAD-7). Although there have been some studies using bsTBS in this
population, to our knowledge this is the first study that does so in a naturalistic tertiary care
setting in a highly resistant MDD population.
Our response and remission rates are higher than what was reported in a preliminary
meta-analysis of TBS studies (52% vs. 35.6% and 28% vs. 18.6% respectively) (Berlim et al.,
2017). Our findings are consistent with the findings in the Li et al. (2014) study in which
combined cTBS and iTBS resulted in 66.7% response rate in the group randomized to this arm
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(n=15). The order of treatment (right pfc cTBS then left iTBS vs. left iTBS then right cTBS) was
randomized and the target of stimulation was the junction between Broddmann 9 and 46, which
was identified stereotactically based on the individual’s MRI. Each side received 1800 pulses per
session. It is likely that providing right then left stimulation using inhibitory (cTBS) then
excitatory (iTBS) stimuli, has some advantage over standard unilateral rTMS because of the high
efficiency of the theta-burst paradigm in inducing neuroplastic changes and the possibility of
affecting a broader distribution of stimulation sites to include right and left frontal-limbic
circuits. For instance, TBS has been shown to reliably alter the excitation/inhibition imbalance
both at the target and distant cortical sites relevant to the pathophysiology of depression
(Iwabuchi et al., 2017; Li et al., 2018). In a previous study comparing 4-weeks of iTBS only with
conventional rTMS, there was no notable physiological differences in resting fMRI connectivity
or cerebral blood flow after 12 weeks (Iwabuchi et al., 2019). This is likely attributed to a small
sample with less severe TRD, resulting in comparable response rates between iTBS and
conventional rTMS. The Berlim et al. (2017) meta-analysis also highlights that sequential TBS is
the most promising method of TBS treatment for TRD (Berlim et al., 2017). Further mechanistic
studies are required to clarify the neural basis of the advantage of bsTBS.
Important limitations to bear in mind, this study was an open-label, retrospective chart
review study, and as such is vulnerable to bias. On the other hand, the treatment resistance of the
population, rating consistency between clinicians (HAMD-17) and patients (PHQ-9), and the
high rate of response and remission, point to a genuine treatment effect. Another limitation is
that the Magstim Super Rapid 2 system limits the level of energy delivered using theta-burst at
high energy, which led to reducing the burst frequency to between 40-50 Hz. This burst
frequency is still however within the gamma burst frequency range and was delivered in a theta-
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burst triplet pattern at 90-100% of the individual’s resting-motor threshold. Other commercially
available machines are now able to deliver the theta-burst frequency at 50 Hz at higher energy
levels, which may offer further advantage. Another limitation is related to localization of
treatment using an approximation method (Beam F3). While neuro-navigation would have
increased the accuracy of targeting, it would not be as easy to use in real-life clinics given the
cost and the labour extensive nature of using neuro-navigation systems. In this study we had data
on 50 participants who completed 20 sessions of treatment. Other studies have shown that
extending the treatment to 30 sessions can add advantage on treatment response (Carpenter et al.,
2012). We plan to extend our treatment paradigm to 30 sessions to assess whether this would
increase the rate of remission and response. Another factor that needs to be considered is the
number of pulses. In Li et al study (Li et al Brain 2014) the number of pulses was higher than our
study (1800 vs. 600 pulses right PFC cTBS and left PFC iTBS), which might have accounted to
the higher response rate (66.7% compared to 52% respectively). This study did not explore the
sustainability of response over time. This is an important issue for future studies.
In summary, for the first time, we report naturalistic data on using bilateral TBS in multitherapy resistant depressed subjects, demonstrating good tolerability and higher than expected
response rates based on unilateral applications. Our data raises the question of the mechanistic
differences between unilateral and sequenced bilateral TBS applications. We call for further
pragmatic and randomised studies using this approach to demonstrate superior patient benefit.
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Figure 1: Participant scores on the HAMD-17, PHQ-9, and GAD-7 before and after 20
treatments of bilateral sequential theta burst stimulation.
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Table 1: Adverse events experienced in the course of 20 treatments of bilateral sequential theta
burst stimulation.

Adverse Events (Over 20 Treatments)
Muscle Contractions
Mild Pain or Discomfort
Post-Tx Diastolic BP Drop (>10mmHg)
Post-Tx (Only) Headache
Post-Tx Diastolic BP Rise (>10mmHg)
Post-Tx Systolic BP Drop (>10mmHg)
Scalp Irritation
Post-Tx Heart Rate Drop (>15bpm)
Post-Tx Heart Rate Rise (>15bmp)
Post-Tx Systolic BP Drop (>10mmHg)
Syncope

Percent
Endorsement
(% of n = 46)
100.00
76.09
67.39
56.52
47.83
34.78
26.09
21.74
6.52
6.52
4.35 (n = 2)

Average Frequency if
Endorsed (% ± 1 SD)
94.67 ± 14.08
68.29 ± 35.29
10.97 ± 7.00
21.54 ± 27.01
9.55 ± 6.53
6.88 ± 4.43
78.75 ± 30.61
6.50 ± 3.37
8.33 ± 5.77
6.67 ± 2.89
5.00 (n = 2)
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